Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial

Background and aims: Randomized clinical trials have demonstrated the ability of glucagon-like peptide-1 analogues (GLP-1RAs) to reduce atherosclerotic cardiovascular disease events in patients with type 2 diabetes (T2D). How GLP-1RAs modulate diabetic atherosclerosis remains to be determined yet. M...

Full description

Bibliographic Details

Published in:	Atherosclerosis Plus
Main Authors:	Yu Kataoka, Satoshi Kitahara, Sayaka Funabashi, Hisashi Makino, Masaki Matsubara, Miki Matsuo, Yoko Omura-Ohata, Ryo Koezuka, Mayu Tochiya, Tamiko Tamanaha, Tsutomu Tomita, Kyoko Honda-Kohmo, Michio Noguchi, Kota Murai, Kenichiro Sawada, Takamasa Iwai, Hideo Matama, Satoshi Honda, Masashi Fujino, Kazuhiro Nakao, Shuichi Yoneda, Kensuke Takagi, Fumiyuki Otsuka, Yasuhide Asaumi, Kiminori Hosoda, Stephen J. Nicholls, Satoshi Yasuda, Teruo Noguchi
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Subjects:	Glucagon-like peptide-1 analogues Lipidic plaque Coronary atherosclerosis Type 2 diabetes mellitus Intravascular ultrasound Near-infrared spectroscopy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667089524000099